Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Tuesday, December 31, 2024.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q4 FY2024 (2024-12-31): -395.28%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
N/A
RETURN ON EQUITY (ROE) AVG 3Y
-189.12%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
NeuroSense Therapeutics Ltd.
Market Cap
$6.95M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
-189.12%
5Y Avg
N/A
Market Cap
$6.97M
Return on Equity (ROE)
-370.16%
TTM Avg
-148.31%
3Y Avg
-87.53%
5Y Avg
-43.20%
Market Cap
$7.00M
Return on Equity (ROE)
-111.46%
TTM Avg
-348.97%
3Y Avg
-374.13%
5Y Avg
-408.25%
Market Cap
$6.87M
Return on Equity (ROE)
-227.37%
TTM Avg
-118.13%
3Y Avg
-87.25%
5Y Avg
-55.09%
Market Cap
$7.07M
Return on Equity (ROE)
-218.65%
TTM Avg
-54.74%
3Y Avg
-35.36%
5Y Avg
-35.36%
Market Cap
$6.82M
Return on Equity (ROE)
-847.90%
TTM Avg
-134.62%
3Y Avg
-211.14%
5Y Avg
-242.56%
Market Cap
$6.72M
Return on Equity (ROE)
N/A
TTM Avg
-266.00%
3Y Avg
851.50%
5Y Avg
629.05%
Market Cap
$7.21M
Return on Equity (ROE)
-225.67%
TTM Avg
-236.53%
3Y Avg
-220.64%
5Y Avg
-186.37%
Market Cap
$6.60M
Return on Equity (ROE)
-54.09%
TTM Avg
-388.62%
3Y Avg
-105.04%
5Y Avg
-44.72%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NeuroSense Therapeutics Ltd. (NRSN) | $6.95M | N/A | N/A | -189.12% | N/A |
| Co-Diagnostics, Inc. (CODX)vs › | $6.97M | -370.16% | -148.31% | -87.53% | -43.20% |
| KALA BIO, Inc. (KALA)vs › | $7.00M | -111.46% | -348.97% | -374.13% | -408.25% |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.87M | -227.37% | -118.13% | -87.25% | -55.09% |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.07M | -218.65% | -54.74% | -35.36% | -35.36% |
| Exicure, Inc. (XCUR)vs › | $6.82M | -847.90% | -134.62% | -211.14% | -242.56% |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.72M | N/A | -266.00% | 851.50% | 629.05% |
| Longeveron Inc. (LGVN)vs › | $7.21M | -225.67% | -236.53% | -220.64% | -186.37% |
| Aclarion, Inc. (ACON)vs › | $6.60M | -54.09% | -388.62% | -105.04% | -44.72% |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.65M | -108.00% | -445.77% | -254.63% | -239.85% |
ROE
N/A
ROA
-1082.2%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2024-12-31 | -395.28% |
| 2023-03-31 | -434.37% |
| 2022-12-31 | -219.61% |
| 2022-09-30 | -118.42% |
| 2022-06-30 | -73.05% |
| 2022-03-31 | -38.26% |
| 2021-12-31 | -44.87% |
| 2021-06-30 | -561.15% |
| 2021-03-31 | -704.25% |
| 2020-12-31 | -429.14% |
